OA03.03 Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703/HPTN 081)Oral Abstract SessionBroadly neutralizing antibodies
OA03.04LB Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial (HVTN 703/HPTN 081 and HVTN 704/085)Oral Abstract SessionBroadly neutralizing antibodies
OA03.05LB HIV-1 bnAb M4008_N1 targets a novel site of vulnerability at the V3 crownOral Abstract SessionBroadly neutralizing antibodies
OA04.01 User assessment of a microarray patch for HIV PrEP and as a multipurpose prevention technology for HIV and pregnancy prevention: perspectives from Uganda and South AfricaOral Abstract SessionBehavioural and social science research
OA04.02 High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamideOral Abstract SessionPreclinical studies for HIV prevention
OA04.03 Distribution of long-acting (LA) cabotegravir (CAB) in plasma, mucosal tissues, and associated fluids after a single ultrasound-guided intramuscular (IM) injection in healthy adult participantsOral Abstract SessionPharmacology/PK and PD studies
OA04.04 Design and testing of a cabotegravir reservoir implant for HIV preventionOral Abstract SessionDelivery technologies: novel approaches, formulation and multi-purpose
OA04.05LB Trial design, enrollment status, demographics, and pharmacokinetics (PK) data from a blinded interim analysis from a phase 2a trial of Islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP)Oral Abstract SessionClinical trial results
OA05.01 Role of HLA-E antigen presentation on NK control of HIV infection Oral Abstract SessionInnate and trained immunity
OA05.02 Acute SIV Induces BHLH gene variants prior to adaptive natural killer cell formationOral Abstract SessionInnate and trained immunity
seek-warrow-warrow-eseek-e91 - 100 of 444 items